We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Genetic Biomarker Links Kidney Disease to African Descent

By LabMedica International staff writers
Posted on 10 Jun 2010
A genetic biomarker was isolated for a potentially fatal kidney disease and could lead to new therapeutic approaches and save more lives.

Israeli scientists studied data from hospitals in the New York region pertaining to Black Americans and Hispanics who could have originated anywhere in the United States. More...
In the previous two years American scientists had traced a genetic link to Africa, when they discovered that end stage kidney diseases (ESKD) is associated with the gene MYH9 found on chromosome 22, which explained the higher prevalence of the disease in those of African Hispanic descent. Previously, scientists had attributed this phenomenon to environmental factors such as culture, or diet.

Israeli and American scientists identified a new biomarker that can help America's medical community to predict who is likely to develop a potentially fatal, end-stage kidney disease most prevalent among Black Americans.

In areas in the United States where there are equal numbers of blacks and whites, more people of African descent will be using a hospital's dialysis machines, followed by those of Latino heritage, with whites in the minority for this condition, said Dr. Doron Behar of the Rambam Medical Center (Haifa, Israel), coauthor of the new study.

In North America alone, there are about 40 million people with chronic kidney disease at varying stages of development. About half of these will go on to develop ESKD. The toll on the healthcare system is enormous and the pain and suffering from treatments and the wait for a transplant can be almost unbearable.

ESKD requires either long-term dialysis or a kidney transplant to keep patients alive and remains fatal in parts of the world where such advanced treatments are not available. Black Americans have about a four-fold higher rate of developing the end-stage disease, and Hispanic-Americans an approximately two-fold higher rate, than Americans of European ancestry.

Interestingly, four years earlier the Israeli scientists in the study found that unlike African-Americans, Ethiopian Africans appear to be protected from end-stage kidney disease. This suggests that something in their genes--also African at the core--may hold the clue as to how kidney health is genetically programmed.

Dr. Behar expects that the genotyping of those who come to their clinics will help nephrologists to save more lives, by providing them with the information to understand and evaluate the risks that their patients may be facing. Knowing who is at risk can help physicians prescribe the appropriate medication to minimize damage to kidneys, as certain drugs can actually cause severe kidney damage in some people.

The authors wrote, ''These findings strengthen the contention that a sequence variant of MYH9, common in populations with varying degrees of African ancestry admixture, and in strong linkage disequilibrium with the associated single nucleotide polymorphisms (SNPs) and haplotypes reported herein, strongly predisposes to nondiabetic ESKD.

The new collaborative study was published in the May 1, 2010 issue of the journal Human Molecular Genetics.

Related Links:
Rambam Medical Center



Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Influenza Virus Test
NovaLisa Influenza Virus B IgM ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.